View More
Expert faculty discusses FGFR signaling, possible consequences of FGFR alterations in tumor development, and current FGFR testing methods and prognostic value.
Prof. Dr. Arndt Hartmann
Released: April 9, 2021
An expert’s thoughts on what healthcare professionals need to know about FGFR alterations and targeted therapies for bladder cancer.
Andrea Necchi, MD
Released: April 30, 2021
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.